UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus : Results from a controlled randomized study

Circulation (New York, N.Y.), 2005-05, Vol.111 (19), p.2525-2531

2005

Volltextzugriff (PDF)

Effects of pioglitazone in non-diabetic patients with arterial hypertension: A double-blind, placebo-controlled study

The journal of clinical endocrinology and metabolism, 2002-12, Vol.87 (12), p.5503-5506

2002

Volltextzugriff (PDF)

Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease

Atherosclerosis, 2008-03, Vol.197 (1), p.311-317

2008

Volltextzugriff (PDF)

Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study

Current medical research and opinion, 2006-06, Vol.22 (6), p.1211-1215

2006

Volltextzugriff (PDF)

Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual β-cell function: results from the PioSwitch Study

Diabetes, obesity & metabolism, 2009-05, Vol.11 (5), p.464-471

2009

Volltextzugriff (PDF)

Visfatin: A Putative Biomarker for Metabolic Syndrome is not Influenced by Pioglitazone or Simvastatin Treatment in Nondiabetic Patients at Cardiovascular Risk - Results from the PIOSTAT Study

Hormone and metabolic research, 2007-10, Vol.39 (10), p.764-768

2007

Volltextzugriff (PDF)

Review of the pleiotropic effects of peroxisome proliferator-activated receptor gamma agonists on platelet function

Diabetes technology & therapeutics, 2007-10, Vol.9 (5), p.410-420

2007

Volltextzugriff (PDF)

Changes in insulin resistance and cardiovascular risk induced by PPARgamma activation have no impact on RBP4 plasma concentrations in nondiabetic patients

Hormone and metabolic research, 2009-03, Vol.41 (3), p.202

2009

Volltextzugriff (PDF)

IRIS II study: the IRIS II score-assessment of a new clinical algorithm for the classification of insulin resistance in patients with Type 2 diabetes

Diabetic medicine, 2004-10, Vol.21 (10), p.1149-1153

2004

Volltextzugriff (PDF)

The IRIS III study: pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight

Diabetes, obesity & metabolism, 2007-01, Vol.9 (1), p.132-133

2007

Volltextzugriff (PDF)

Pioglitazon vermindert das kardiovaskuläre Risiko bei Typ-2-Diabetespatienten

Diabetologe, 2008-11, Vol.4 (7), p.542-548

2008

Volltextzugriff (PDF)

Intermittent Complete Androgen Blockade in PSA Relapse after Radical Prostatectomy and Incidental Prostate Cancer

European urology, 1999-01, Vol.35 (Suppl 1), p.27-31

1999

Volltextzugriff (PDF)

Pharmacological PPARγ Stimulation in Contrast to Beta Cell Stimulation Results in an Improvement in Adiponectin and Proinsulin Intact Levels and Reduces Intima Media Thickness in Patients with Type 2 Diabetes

Hormone and metabolic research, 2005-08, Vol.37 (8), p.521-527

2005

Volltextzugriff (PDF)

Coefficient of beta-cell failure in patients with type 2 diabetes treated with pioglitazone or acarbose

Experimental and clinical endocrinology & diabetes, 2004-02, Vol.112 (2), p.115-117

2004

Volltextzugriff (PDF)

Effects of Pioglitazone in Nondiabetic Patients with Arterial Hypertension: A Double-Blind, Placebo-Controlled Study

The journal of clinical endocrinology and metabolism, 2002-12, Vol.87 (12), p.5503-5506

2002

Volltextzugriff (PDF)

Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis

Gynecological endocrinology, 2001-06, Vol.15 (3), p.202-209

2001

Volltextzugriff (PDF)

Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control : Results from the pioneer study

Journal of the American College of Cardiology, 2005-06, Vol.45 (12), p.1925-1931

2005

Volltextzugriff (PDF)

Fasting Intact Proinsulin Is a Highly Specific Predictor of Insulin Resistance in Type 2 Diabetes

Diabetes care, 2004-03, Vol.27 (3), p.682-687

2004

Volltextzugriff (PDF)

Efficacy and Safety of Leuprorelin Acetate Depot for Prostate Cancer

Urologia internationalis, 1996, Vol.56 (1), p.23-30

1996

Volltextzugriff (PDF)

Potential role of oral thiazolidinedione therapy in preserving β-cell function in type 2 diabetes mellitus

Drugs (New York, N.Y.), 2005, Vol.65 (1), p.1-13

2005

Volltextzugriff (PDF)

Pioneer Study: PPARγ Activation Results in Overall Improvement of Clinical and Metabolic Markers Associated with Insulin Resistance Independent of Long-term Glucose Control

Hormone and metabolic research, 2005-08, Vol.37 (8), p.510-515

2005

Volltextzugriff (PDF)

Ödementwicklung unter Pioglitazontherapie: BNP ist ein möglicher Indikator für das Risiko zur Entwicklung einer Herzinsuffizienz bei Patienten mit Typ 2 Diabetes mit Glitazontherapie

Diabetologie und Stoffwechsel, 2007, Vol.2 (S 1)

2007

Volltextzugriff (PDF)

Prävalenz unentdeckter Diabeteserkrankungen bei Patienten von kardiologischen Schwerpunkteinrichtungen

Diabetologie und Stoffwechsel, 2007, Vol.2 (S 1)

2007

Volltextzugriff (PDF)

Pioglitazon verbessert das kardiovaskuläre Risikoprofil bei nicht-diabetischen Patienten

Diabetologie und Stoffwechsel, 2007, Vol.2 (S 1)

2007

Volltextzugriff (PDF)

Evaluation der Wertigkeit von RBP4 als Marker des metabolischen Syndroms in einer prospektiven Interventionsstudie mit Pioglitazon

Diabetologie und Stoffwechsel, 2007, Vol.2 (S 1)

2007

Volltextzugriff (PDF)

1 – 25 von 203

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(185)
Mit Volltextzugriff
(149)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(110)
Life Sciences & Biomedicine
(79)
Humans
(53)
Biological And Medical Sciences
(49)
Medical Sciences
(34)
Physical Sciences
(32)
Animals
(31)
Female
(26)
Pharmacology & Pharmacy
(25)
Pharmacology. Drug Treatments
(25)
Aged
(24)
Chemistry
(24)
Male
(24)
Biochemistry & Molecular Biology
(19)
Middle Aged
(18)
Diabetes Mellitus, Type 2 - Drug Therapy
(16)
Fundamental And Applied Biological Sciences. Psychology
(16)
Structure-Activity Relationship
(15)
Microbiology
(13)
Chemistry, Medicinal
(12)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus : Results from a controlled randomized study

Effects of pioglitazone in non-diabetic patients with arterial hypertension: A double-blind, placebo-controlled study

Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease

Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study

Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual β-cell function: results from the PioSwitch Study

Visfatin: A Putative Biomarker for Metabolic Syndrome is not Influenced by Pioglitazone or Simvastatin Treatment in Nondiabetic Patients at Cardiovascular Risk - Results from the PIOSTAT Study

Review of the pleiotropic effects of peroxisome proliferator-activated receptor gamma agonists on platelet function

Changes in insulin resistance and cardiovascular risk induced by PPARgamma activation have no impact on RBP4 plasma concentrations in nondiabetic patients

IRIS II study: the IRIS II score-assessment of a new clinical algorithm for the classification of insulin resistance in patients with Type 2 diabetes

The IRIS III study: pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight

Pioglitazon vermindert das kardiovaskuläre Risiko bei Typ-2-Diabetespatienten

Intermittent Complete Androgen Blockade in PSA Relapse after Radical Prostatectomy and Incidental Prostate Cancer

Pharmacological PPARγ Stimulation in Contrast to Beta Cell Stimulation Results in an Improvement in Adiponectin and Proinsulin Intact Levels and Reduces Intima Media Thickness in Patients with Type 2 Diabetes

Coefficient of beta-cell failure in patients with type 2 diabetes treated with pioglitazone or acarbose

Effects of Pioglitazone in Nondiabetic Patients with Arterial Hypertension: A Double-Blind, Placebo-Controlled Study

Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis

Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control : Results from the pioneer study

Fasting Intact Proinsulin Is a Highly Specific Predictor of Insulin Resistance in Type 2 Diabetes

Efficacy and Safety of Leuprorelin Acetate Depot for Prostate Cancer

Potential role of oral thiazolidinedione therapy in preserving β-cell function in type 2 diabetes mellitus

Pioneer Study: PPARγ Activation Results in Overall Improvement of Clinical and Metabolic Markers Associated with Insulin Resistance Independent of Long-term Glucose Control

Ödementwicklung unter Pioglitazontherapie: BNP ist ein möglicher Indikator für das Risiko zur Entwicklung einer Herzinsuffizienz bei Patienten mit Typ 2 Diabetes mit Glitazontherapie

Prävalenz unentdeckter Diabeteserkrankungen bei Patienten von kardiologischen Schwerpunkteinrichtungen

Pioglitazon verbessert das kardiovaskuläre Risikoprofil bei nicht-diabetischen Patienten

Evaluation der Wertigkeit von RBP4 als Marker des metabolischen Syndroms in einer prospektiven Interventionsstudie mit Pioglitazon

Suchergebnisse filtern